Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million

Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) announced that underwriters fully exercised their over-allotment option, increasing total proceeds from its follow-on public offering to $10.35 million. This closing is expected on or about February 10, 2021. The funds will primarily be used for the development of the company's lead drug candidate, a novel immuno-oncology gene therapy targeting multiple cancers. The offering statement was filed with the SEC on January 26, 2021.

Positive

• Total proceeds from the offering reached $10.35 million.
• Proceeds will be used for further development of the lead drug candidate, which shows potential for growth.

Negative

• None.

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company's follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million.

The exercise of the over-allotment option is expected to close on or about February 10, 2021, subject to customary closing conditions.

Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.  The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.

Scopus intends to use the total proceeds of the follow-on public offering, including the proceeds from the exercise of the over-allotment option, principally for further development of the company's lead drug candidate, including in combination with checkpoint inhibitors.

The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.

Greenberg Traurig, LLP is acting as counsel to the company.  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as counsel to the underwriters.

An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021. The offering is being made only by means of an offering circular, copies of which may be obtained, when available, by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at prospectus@benchmarkcompany.com; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at prospectus@jgunnar.com.  The offering circular is also available on the U.S. Securities and Exchange Commission website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions.  The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.  This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.  The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.

Forward-Looking Statements

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

Contact

Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/underwriters-exercise-over-allotment-option-in-full-brings-total-follow-on-public-offering-proceeds-to-10-35-million-301224370.html

SOURCE Scopus BioPharma Inc.

FAQ

What is the total proceeds from Scopus BioPharma's follow-on public offering?

The total proceeds from the follow-on public offering reached $10.35 million.

When is the closing date for the exercise of the over-allotment option by Scopus BioPharma?

The closing date is expected on or about February 10, 2021.

What is Scopus BioPharma's lead drug candidate used for?

The lead drug candidate is a novel immuno-oncology gene therapy for the treatment of multiple cancers.

How will Scopus BioPharma use the proceeds from the offering?

The proceeds will primarily be used for the further development of the lead drug candidate, including in combination with checkpoint inhibitors.